Page 40 - MI-2-2

Microbes & Immunity Genetic therapy with HSV-1 vectors

expressing ICP34.5 under the transcriptional control of doi: 10.1016/j.athoracsur.2005.01.048
musashi1 promoter in the treatment of malignant glioma. 78. Liu BL, Robinson M, Han, et al. ICP34.5 deleted herpes
Hum Gene Ther. 2007;18(1):63-73.
simplex virus with enhanced oncolytic, immune stimulating,
doi: 10.1089/hum.2006.107 and anti-tumour properties. Gene Ther. 2003;10(4):292-303.
69. Ushijima Y, Luo C, Goshima F, Yamauchi Y, Kimura H, doi: 10.1038/sj.gt.3301885
Nishiyama Y. Determination and analysis of the DNA 79. Hocknell PK, Wiley RD, Wang X, et al. Expression of human
sequence of highly attenuated herpes simplex virus type 1 immunodeficiency virus type 1 gp120 from herpes simplex
mutant HF10, a potential oncolytic virus. Microbes Infect. virus type 1-derived amplicons results in potent, specific,
2007;9(2):142-149.
and durable cellular and humoral immune responses.
doi: 10.1016/j.micinf.2006.10.019 J Virol. 2002;76(11):5565-5580.
70. Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic doi: 10.1128/jvi.76.11.5565-5580.2002
viral therapy using mutant herpes simplex virus (HF10)
against recurrent metastatic breast cancer. Ann Surg Oncol. 80. Santos K, Duke CM, Dewhurst S. Amplicons as vaccine
2006;13(8):1078-1084. vectors. Curr Gene Ther. 2006;6(3):383-392.
doi: 10.2174/156652306777592009
doi: 10.1245/ASO.2006.08.035
81. Tyler CM, Wuertzer CA, Bowers WJ, Federoff HJ.
71. Fujimoto Y, Mizuno T, Sugiura S, et al. Intratumoral HSV amplicons: Neuro applications. Curr Gene Ther.
injection of herpes simplex virus HF10 in recurrent head 2006;6(3):337-350.
and neck squamous cell carcinoma. Acta Otolaryngol.
2006;126(10):1115-1117. doi: 10.2174/156652306777592045
doi: 10.1080/00016480600702100 82. Sena-Esteves M, Hampl JA, Camp SM, Breakefield XO.
Generation of stable retrovirus packaging cell lines after
72. Rainov NG, Sena-Esteves M, Fraefel C, Dobberstein KU,
Chiocca EA, Breakefield XO. A chimeric fusion protein transduction with herpes simplex virus hybrid amplicon
of cytochrome CYP4B1 and green fluorescent protein vectors. J Gene Med. 2002;4(3):229-239.
for detection of pro-drug activating gene delivery and doi: 10.1002/jgm.276
for gene therapy in malignant glioma. Adv Exp Med Biol. 83. Tsitoura E, Lucas M, Revol-Guyot V, Epstein AL,
1998;451:393-403. Manservigi R, Mavromara P. Expression of hepatitis C virus
doi: 10.1007/978-1-4615-5357-1_61 envelope glycoproteins by herpes simplex virus type 1-based
amplicon vectors. J Gen Virol. 2002;83(Pt 3):561-566.
73. Jacobs AH, Winkeler A, Hartung M, et al. Improved herpes
simplex virus type 1 amplicon vectors for proportional doi: 10.1099/0022-1317-83-3-561
coexpression of positron emission tomography marker and 84. Hong Z, Ferrari E, Wright-Minogue J, et al. Enzymatic
therapeutic genes. Hum Gene Ther. 2003;14(3):277-297.
characterization of hepatitis C virus NS3/4A complexes
doi: 10.1089/10430340360535823 expressed in mammalian cells by using the herpes simplex
virus amplicon system. J Virol. 1996;70(7):4261-4268.
74. Liu S, Dai M, You L, Zhao Y. Advance in herpes simplex viruses
for cancer therapy. Sci China Life Sci. 2013;56(4):298-305. doi: 10.1128/jvi.70.7.4261-4268.1996
doi: 10.1007/s11427-013-4466-4 85. Watanabe D, Brockman MA, Ndung’u T, et al. Properties
of a herpes simplex virus multiple immediate-early
75. Kim SH, Wong RJ, Kooby DA, et al. Combination of mutated gene-deleted recombinant as a vaccine vector. Virology.
herpes simplex virus type 1 (G207 virus) with radiation for
the treatment of squamous cell carcinoma of the head and 2007;357(2):186-198.
neck. Eur J Cancer. 2005;41(2):313-322. doi: 10.1016/j.virol.2006.08.015
doi: 10.1016/j.ejca.2004.10.018 86. Hoshino Y, Dalai SK, Wang K, et al. Comparative efficacy
and immunogenicity of replication-defective, recombinant
76. Jarnagin WR, Zager JS, Hezel M, et al. Treatment of
cholangiocarcinoma with oncolytic herpes simplex virus glycoprotein, and DNA vaccines for herpes simplex virus 2
combined with external beam radiation therapy. Cancer infections in mice and guinea pigs. J Virol. 2005;79(1):410-418.
Gene Ther. 2006;13(3):326-334. doi: 10.1128/JVI.79.1.410-418.2005
doi: 10.1038/sj.cgt.7700890 87. Lauterbach H, Kerksiek KM, Busch DH, et al. Protection
from bacterial infection by a single vaccination with
77. Adusumilli PS, Stiles BM, Chan MK, et al. Radiation therapy
potentiates effective oncolytic viral therapy in the treatment replication-deficient mutant herpes simplex virus type 1.
of lung cancer. Ann Thorac Surg. 2005;80(2):409-416; J Virol. 2004;78(8):4020-4028.
discussion 416-7. doi: 10.1128/jvi.78.8.4020-4028.2004

Volume 2 Issue 2 (2025) 32 doi: 10.36922/mi.7947